- Home
- BWMX vs ERAS Comparison
BWMX vs ERAS Comparison
Compare BWMX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWMX
- ERAS
- Stock Information
- Founded
- BWMX 1995
- ERAS 2018
- Country
- BWMX Mexico
- ERAS United States
- Employees
- BWMX N/A
- ERAS N/A
- Industry
- BWMX Catalog/Specialty Distribution
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- BWMX Consumer Discretionary
- ERAS Health Care
- Exchange
- BWMX Nasdaq
- ERAS Nasdaq
- Market Cap
- BWMX 495.6M
- ERAS 439.7M
- IPO Year
- BWMX N/A
- ERAS 2021
- Fundamental
- Price
- BWMX N/A
- ERAS $2.43
- Analyst Decision
- BWMX Strong Buy
- ERAS Buy
- Analyst Count
- BWMX 2
- ERAS 6
- Target Price
- BWMX $22.50
- ERAS $3.83
- AVG Volume (30 Days)
- BWMX 31.8K
- ERAS 2.3M
- Earning Date
- BWMX 10-23-2025
- ERAS 11-11-2025
- Dividend Yield
- BWMX 11.38%
- ERAS N/A
- EPS Growth
- BWMX N/A
- ERAS N/A
- EPS
- BWMX 0.84
- ERAS N/A
- Revenue
- BWMX $751,432,052.00
- ERAS N/A
- Revenue This Year
- BWMX $6.54
- ERAS N/A
- Revenue Next Year
- BWMX $6.09
- ERAS N/A
- P/E Ratio
- BWMX $15.42
- ERAS N/A
- Revenue Growth
- BWMX 4.83
- ERAS N/A
- 52 Week Low
- BWMX $7.00
- ERAS $1.01
- 52 Week High
- BWMX $14.46
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- BWMX 51.18
- ERAS 73.25
- Support Level
- BWMX $12.80
- ERAS $2.21
- Resistance Level
- BWMX $13.54
- ERAS $2.65
- Average True Range (ATR)
- BWMX 0.27
- ERAS 0.21
- MACD
- BWMX -0.09
- ERAS 0.06
- Stochastic Oscillator
- BWMX 41.48
- ERAS 89.39
About BWMX Betterware de Mexico S.A.P.I. de C.V.
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.